These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26152649)

  • 1. Effects of Changes in Diabetes Pay-for-Performance Incentive Designs on Patient Risk Selection.
    Hsieh HM; Tsai SL; Mau LW; Chiu HC
    Health Serv Res; 2016 Apr; 51(2):667-86. PubMed ID: 26152649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of diabetes pay-for-performance incentive designs.
    Hsieh HM; Tsai SL; Shin SJ; Mau LW; Chiu HC
    Med Care; 2015 Feb; 53(2):106-15. PubMed ID: 25397966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program?
    Chen TT; Chung KP; Lin IC; Lai MS
    Health Serv Res; 2011 Feb; 46(1 Pt 1):47-60. PubMed ID: 20880044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Pay-for-Performance Incentive Designs on Diabetes Care.
    Hsieh HM; Shin SJ; Tsai SL; Chiu HC
    Med Care; 2016 Dec; 54(12):1063-1069. PubMed ID: 27479599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of individual and neighborhood social risks on diabetes pay-for-performance program under a single-payer health system.
    Tsai WC; Huang KH; Chen PC; Chang YC; Chen MS; Lee CB
    Soc Sci Med; 2023 Jun; 326():115930. PubMed ID: 37146356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group.
    Cutler TW; Palmieri J; Khalsa M; Stebbins M
    J Manag Care Pharm; 2007 Sep; 13(7):578-88. PubMed ID: 17874864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?
    Tan EC; Pwu RF; Chen DR; Yang MC
    Qual Life Res; 2014 Mar; 23(2):687-96. PubMed ID: 23975377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study.
    Hsieh HM; Lin TH; Lee IC; Huang CJ; Shin SJ; Chiu HC
    Prev Med; 2016 Apr; 85():53-59. PubMed ID: 26740347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a PPO pay-for-performance program on patients with diabetes.
    Chen JY; Tian H; Taira Juarez D; Hodges KA; Brand JC; Chung RS; Legorreta AP
    Am J Manag Care; 2010 Jan; 16(1):e11-9. PubMed ID: 20059287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between the pay-for-performance scheme and better physician-patient relationship might reduce the risk of retinopathy in patients with type 2 diabetes.
    Chiou SJ; Liao K; Huang YT; Lin W; Hsieh CJ
    J Diabetes Investig; 2021 May; 12(5):819-827. PubMed ID: 33025682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of clinical guideline adherence and pay-for-performance among patients with diabetes.
    Lai CL; Hou YH
    J Chin Med Assoc; 2013 Feb; 76(2):102-7. PubMed ID: 23351421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient assessment of diabetes care in a pay-for-performance program.
    Chiu HC; Hsieh HM; Lin YC; Kuo SJ; Kao HY; Yeh SC; Chang WH; Hsiao PJ; Chen YS; Lin SL; Lo GH; Ker CG; Hung YH; Cheng HA; Chou TH; Chou SY; Wang JH; Wang CF
    Int J Qual Health Care; 2016 Apr; 28(2):183-90. PubMed ID: 26819445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-specific Pay-for-Performance Programs: Do the P4P Effects Differ Between Diabetic Patients With and Without Multiple Chronic Conditions?
    Huang YC; Lee MC; Chou YJ; Huang N
    Med Care; 2016 Nov; 54(11):977-983. PubMed ID: 27547944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Taiwan's pay-for-performance program for diabetes care: a cost-benefit net value approach.
    Lu JR; Chen YI; Eggleston K; Chen CH; Chen B
    Eur J Health Econ; 2023 Jul; 24(5):717-733. PubMed ID: 35995886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the Long-term Spillover Effects of a Pay-for-Performance Program in a Healthcare System That Lacks Referral Arrangements.
    Chen CC; Chien KL; Cheng SH
    Int J Health Policy Manag; 2023; 12():7571. PubMed ID: 38618790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors related to continuing care and interruption of P4P program participation in patients with diabetes.
    Yen SM; Kung PT; Sheen YJ; Chiu LT; Xu XC; Tsai WC
    Am J Manag Care; 2016 Jan; 22(1):e18-30. PubMed ID: 26799201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and provider factors associated with enrolment in the pre-end-stage renal disease pay-for-performance programme in Taiwan: a cross-sectional study.
    Hu HY; Jian FX; Lai YJ; Yen YF; Huang N; Hwang SJ
    BMJ Open; 2019 Sep; 9(9):e031354. PubMed ID: 31519682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pay-for-performance for shared care of diabetes in Taiwan.
    Lee IT; Hsu CC; Sheu WH; Su SL; Wu YL; Lin SY
    J Formos Med Assoc; 2019 Nov; 118 Suppl 2():S122-S129. PubMed ID: 31471222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a schizophrenia pay-for-performance program on patient outcomes in Taiwan.
    Chen TT; Yang JJ; Hsueh YA; Wang V
    Health Serv Res; 2019 Oct; 54(5):1119-1125. PubMed ID: 31131891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A diabetes pay-for-performance program and the competing causes of death among cancer survivors with type 2 diabetes in Taiwan.
    Hsieh HM; Chiu HC; Lin YT; Shin SJ
    Int J Qual Health Care; 2017 Aug; 29(4):512-520. PubMed ID: 28531317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.